Reviewer #1: Remarks to the Author: The study entitled "The interplay between hypoxia and androgen at glucose-6-phosphate isomerase controls a metabolic switch to reduce the antitumor efficacy of androgen/AR-targeted therapy" addresses two areas in prostate cancer biology, androgen receptor (AR) signaling and hypoxia, that are of great interest to the field but that are rarely studied together. Here, the authors demonstrate that androgen-deprivation therapy (ADT) combined with hypoxia promote the regulation of a subset of genes that contribute towards resistance to the 2nd generation AR antagonist, enzalutamide. Interestingly, AR represses the hypoxia-mediated expression of phosphoglucose isomerase (GPI), a glycolytic enzyme. Hence, under conditions of hypoxia, enzalutamide increases GPI expression, promoting pro-cancer glycolysis as a resistance mechanism. Overall, this is a very well written manuscript that addresses topics that will be of great interest to the broad fields of prostate cancer and cancer metabolism. Importantly, it describes a potential mechanism of drug resistance and therefore sets the stage for novel approaches that could be tried to overcome resistance to AR blockade. The study is supported by exceptional mechanistic studies elucidating how AR and hypoxia modulate GPI expression and activity, xenograft mouse models and clinical correlation data. The main weakness is that there are currently no analyses of metabolic flux. This is important because one of the key points is that this alteration in GPI levels is hypothesized to "reroute" metabolism. Given the number of routes glucose metabolism can take, it is unclear if the changes observed are due to increases in influx or decreases in efflux. Further, there were some missed opportunities where the in vivo tumor samples could have been interrogated more to strengthen the authors conclusions. Below is a more detailed list of issues that should be addressed to further strength this promising study prior to publication.
1) The data supporting the model of metabolic rerouting should ideally be proven using metabolic flux/tracing approaches. This could be done in the cell models and would prove that glucose is being diverted away from the pentose phosphate pathway (PPP) towards glycolysis. In addition, it could be used to determine whether the carbons continue on into the TC A cycle or are converted to lactate (or possibly other pathways including the hexosamine biosynthetic pathway or nonoxidative arm of the PPP, etc). At present, the data is largely looking at snap shots of metabolites that could be increased from either increased production or decreased breakdown, making it difficult to draw conclusions. 2) Related to the point above, contrary to what is stated by the authors, GPI is not widely considered the committed step of glycolysis. GPI catalyzes a reversible reaction. Hence, simply demonstrating increased GPI activity does not necessarily mean more forward flux through glycolysis. Further, the product of GPI, fructose-6-phosphate (F6P), can also enter (or come from) the non-oxidative arm of the PPP. These are additional reasons to do the tracing studies. However, it is noted that the experiments demonstrating knockdown of PFK1, which is a canonical, committed step of glycolysis, do support the authors model. 3) In addition to its effects in glycolysis, GPI has known moonlighting functions outside of the cell that have been demonstrated to contribute towards cancer metastases. This alternative mechanism of action was not considered and should, at a minimum, be addressed in the Discussion. 4) It is surprising that the transient transfection of LAPC 4 cells, which typically have a low transfection efficiency, with a GPI expression plasmid was sufficient to promote a significant level of therapy resistance in a population of cells. C ontrols should be included to demonstrate transfection efficiency and confirm GPI overexpression. 5) GPI levels or activity should be assessed in the tumor samples from Figure 1G to support the model. 6) Given that the functional effects of GPI is a major point of this study and concerns regarding the off-target effects of chemical siRNAs, the experiments described in Figures 5D-G and 6B should be confirmed using multiple siRNAs, an add-back approach or the C RISPR GPI knockout line created and used in Figure 6G . 7) While potentially beyond the scope of this study, evidence of increased glycolysis in the resistant tumors from any of the animal studies would greatly strengthen the data.
Minor points: 1) JQ1 is not a direct AR inhibitor. Rather it indirectly targets AR via associated BRD4.
2) It is not clear why repeated cycles of ADT were needed compared to continuous ADT. 3) C omment: It is worth noting that subcutaneous injection sites are quite hypoxic and hence, without stating so, the authors chose an ideal xenograft model site for their studies. While certainly beyond the scope of this study, it would be interesting to see if similar effects would be observed at other, less hypoxic sites. 4) It is premature to conclude that ATP production and energy homeostasis are the main reasons why glycolysis would be driving disease progression in this context. This was never formally tested and there are many other important aspects of glycolysis that contribute towards tumor growth and cancer spreading. 5) C atalog numbers for the metabolic kits should be provided because it is not clear how they assessed F6P levels. The stated company does not appear to offer an assay kit to quantitate this metabolite, which is often difficult to distinguish from G6P. 6) Where repeated comparisons are made, repeated t tests are likely inadequate. Rather, ANOVAs with appropriate post hoc tests should be used. Reviewer #2: Remarks to the Author: The authors have taken a novel approach to identify factors which can contribute to ADTresistance under conditions of hypoxia. This has evolved the adaptive selection of cell-lines through repeated exposure to hypoxia and ADT. Of the prognostic genes identified in this study the authors have focussed on GPI and its contribution to sustaining glycolysis under conditions of hypoxia once androgen-mediated repression has been removed. The study is provocative and carefully undertaken with respect to GPI. The manuscript will need some minor revisions prior to publication including the full deposition of microarray data in a suitable repository. The authors have used the TC GA dataset to associate the prognostic value of genes that are induced by hypoxia and repressed by androgen but highly expressed under conditions of ADT and hypoxia. They have done so through single-gene analysis. Are all of these prognostic genes differentially expressed in the same subset of TC GA cases? Which pathways are dysregulated in cases identified by these genes? How does the GSEA analysis undertaken in supplementary figure 3 and enrichments shown here map back to these genes? Which genes account for the enrichments attributed to biologies in this analysis -eg. Androgen response or estrogen response. These should be provided in tabular form to provide extra insights. Finally, of the genes that have been reported to be prognostic in the TC GA data, including GPI, are any also known to be regulated by other poor prognosis mutant drivers of prostate cancer -eg. TP53, PTEN etc. This extra information will significantly enhance the impact of this study. Response -As shown in response 1 and 2 above, these two concerns are addressed in our revision, page 8-9/ Figure 5 , and page 11/ Figure 7 , respectively.
Major points:
1) The data supporting the model of metabolic rerouting should ideally be proven using metabolic flux/tracing approaches. This could be done in the cell models and would prove that glucose is being diverted away from the pentose phosphate pathway (PPP) figure 5B -5D, confirms our original hypothesis that there is a glucose metabolic reprogramming from the PPP pathway, including the non-oxidative arm of PPP as seen by metabolite S7P, to the lactate-producing cytosolic glycolytic pathway in response to androgen/ARtargeted therapies in hypoxia. The glucose entry into the TCA cycle is blocked by hypoxia as seen in figure 5D . This is consistent with the well-established concept that hypoxia induce enzymes such as PDK1 to prevent glucose TCA cycle entry, while increasing the production of lactate. The glucose flow to the hexosamine biosynthetic pathway is an interesting possibility; however, we did not detect metabolites along this pathway.
